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Background:  To investigate the clinical results of sitagliptin (SITA) and the characteristics of the treatment failure group or of 
low responders to SITA.
Methods:  A retrospective study of type 2 diabetic patients reviewed 99 cases, including 12 treatment failure cases, who stopped 
SITA because of worsening patients’ condition, and 87 cases, who continued treatment over five visits (total 9.9±10.1 months) 
after receiving the prescription of SITA from December 2008 to June 2009. Subjects were classified as five groups administered 
SITA as an initial combination with metformin (MET), add-on to metformin or sulfonylurea, and switching from sulfonylurea 
or thiazolidinedione. The changes in HbA1c level from the first to last visit (∆HbA1c) in treatment maintenance group were sub-
analyzed.
Results:  The HbA1c level was significantly reduced in four groups, including initial coadministration of SITA with metformin 
(∆HbA1c=-1.1%, P<0.001), add-on to MET (∆HbA1c=-0.6%, P=0.017), add-on to sulfonylurea (∆HbA1c=-0.5%, P<0.001), 
and switching from thiazolidinedione (∆HbA1c=-0.3%, P=0.013). SITA was noninferior to sulfonlyurea (∆HbA1c=-0.2%, 
P=0.63). There was no significant adverse effect. The treatment failure group had a longer diabeties duration (P=0.008), higher 
HbA1c (P=0.001) and fasting plasma glucose (P=0.003) compared to the maintenance group. Subanalysis on the tertiles of 
∆HbA1c showed that low-response to SITA (tertile 1) was associated with a longer diabetes duration (P=0.009) and lower HbA1c 
(P<0.001).
Conclusion:  SITA was effective and safe for use in Korean type 2 diabetic patients. However, its clinical responses and long-term 
benefit–harm profile is yet to be established.
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INTRODUCTION
The prevalence of type 2 diabetes, which is caused by mecha-
nisms such as insulin secretory defect failure and insulin resis-
tance, is rapidly increasing worldwide. To prevent complica-
tions in the early stages of type 2 diabetes occupying 90% to 
95% of South Korean diabetic patients [1], a thorough blood 
glucose management should be established [2]. According to 
the American Diabetes Association (ADA) guidelines and the 
European Association of the Study of Diabetes, initial therapy 
should involve lifestyle changes and metformin (MET) treat-
ment. However, because of the progressive nature of the dis-
ease, combination therapy consisting of two or more drugs or 
insulin therapy is typically necessary over time [3].
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  The main incretin hormones glucagon-like peptide-1 (GLP-
1) and glucose-dependent insulinotropic polypeptide (GIP) 
stimulate insulin synthesis and secretion in the β-cells of the 
pancreas when blood glucose levels are high. The use of a glu-
cagon suppressing hormone from α-cells [4] has resulted in 
significant improvements of differentiation and proliferation 
of β-cells and inhibition of apoptosis in animal model and hu-
man islets [5,6]. In type 2 diabetes patients, GLP-1 secretion 
and GIP function decrease, however, these incretin hormones 
can be increased by inhibition of incretin-disabling enzyme 
dipeptidyl peptidase IV (DPP-IV) [7-9].
  Sitagliptin (SITA), an oral DPP-IV inhibitor has been prov-
en valid and low risk of side effects, such as hypoglycemia and 
weight gain in the treatment of type 2 diabetes. Dhillon [10] 
has reviewed that the addition of SITA to ongoing treatment 
therapies resulted in significant improvements to HbA1c. More-
over, the report showed that SITA was noninferior to glipizide 
and generally did not differ from rosiglitazone. SITA can im-
proved HbA1c without weight gain and rarely results in hypo-
glycemia except for coadminstration with sulfonylurea (SU) or 
insulin. 
  SITA was first used as a DPP-IV inhibitor in South Korea in 
early 2008, and the prevalence of SITA prescription in South 
Korea is increasing. However, results from Korean subjects are 
limited and so more data and research are required. The pres-
ent study was performed in tertiary hospitals, and we investi-




A retrospective study was conducted for patients starting SITA 
therapy for type 2 diabetes between December 2008 and June 
2009, who attended the outpatient clinic at intervals of two to 
three months for a total of five visits.
  The treatment maintenance group was defined as patients 
who continued a daily dose of 100 mg SITA during follow-up 
periods, and the treatment failure group was defined as pa-
tients who had discontinued SITA treatment because of in-
creasing HbA1c level above 7% and worsening patients’ con-
dition. Among a total of 99 patients, 87 belonged to the treat-
ment maintenance group and 12 were included in the treat-
ment failure group. Exclusion criteria was switch from more 
than two different kinds of diabetes medications, voluntary 
discontinuation of SITA treatment, and follow-up loss. The 
cases of SITA switched from or added-on to previous medica-
tions such as meglitinide, α-glucosidase inhibitor or insulin 
were rare, so they were also excluded.
  Patients in the treatment maintenance group were subdi-
vided into five groups: an initial coadministration of SITA 
with MET group, add-on to MET or SU groups, switch from 
SU or thiazolidinedione (TZD) groups. 
  Additionally, for the 87 patients in the treatment mainte-
nance group the changes in HbA1c level from the first to last 
visit (HbA1c at visit 1–HbA1c at visit 5, ∆HbA1c) were used 
to divide into three subgroups. The first tertile group had a low 
response, and the third tertile group had a good response, so 
they were comparatively analyzed. SITA prescription beyond 
coverage of medical insurance was paid privately after the 
consent of the patients.
Explanatory variables and outcome measures 
Fasting plasma glucose levels (FPG) and HbA1c were measured 
in the outpatient clinic. Blood glucose was measured using the 
glucose oxidase method (CX3 DELTA; Beckman, Brea, CA, 
USA); HbA1c was measured using high-performance liquid 
chromatography (Bio-Rad, Richmond, CA, USA); and insulin 
and C-peptide levels were measured using a gamma counter 
(Dream Gamma-10; ShinJin Medics Co., Seoul, Korea). Body 
mass index (BMI) was surveyed within the first year of SITA 
administration, and outpatient records or prescriptions includ-
ing personal history, drugs taken, and side effects were exam-
ined.
Statistical analysis
All measurements were expressed as mean±standard devia-
tion (SD) or as median (25% confidence interval [CI], 75% 
CI]. For discontinuous variables, a chi-square analysis was 
used. For continuous variables, ∆HbA1c and the changes in 
the FPG (∆FPG) during follow-up periods were examined us-
ing the Wilcoxon Signed Rank test because the Kolmogorov-
Smirnov test did not demonstrate normality; the Mann-Whit-
ney test was used for the comparative analysis between the 
treatment failure and maintenance group. For subanalysis, the 
Kruskal-Wallis test was used to compare tertiles of ∆HbA1c in 
the treatment maintenance group. The SPSS for Windows, 
version 17.0, was used for statistical analysis (SPSS Inc., Chi-
cago, IL, USA), and P values less than 0.05 were considered to 
be statistically significant.292
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RESULTS
Baseline characteristics
During the study period, 160 patients were newly prescribed 
with SITA. Over five visits to the outpatient clinic, 87 patients 
maintained the type and amount of antidiabetic medication 
and their mean follow-up period was 9.9±10.1 months. We 
discontinued administration of SITA in the 12 members in the 
treatment failure group with deteriorating blood glucose. Of 
the 99 total participants, the mean age was 53.9±12.0, women 
were 63 (64%), and the duration of diabetes was 4.5±4.9 years.
  The initial coadministration of SITA and MET group in-
cluded 21 patients, the add-on SITA to MET group had 18 pa-
tients, the add-on SITA to SU group had 12 patients, the group 
switched from SU had 22 patients, and the group switched 
from TZD had 14 patients. MET was prescribed to 86% to 100% 
of patients in each group. The age, diabetes duration, HbA1c, 
FPG, fasting insulin level, fasting C-peptide level, and BMI 
were expressed as mean±SD or median (25% CI, 75% CI) and 
gender, history of taking antihypertensive and antihyperlipid-
emic medications were examined as number and percentage 
(Table 1). 
∆HbA1c and ∆FPG before and after SITA administration
The groups that had statistically significant reductions in 
HbA1c level between visit 1 and visit 5 (∆HbA1c) included 
the initial coadministration of SITA and MET group 
(∆HbA1c=-1.1%, P<0.001), the add-on SITA to SU group 
(∆HbA1c=-0.5%, P<0.001), the add-on SITA to MET group 
(∆HbA1c=-0.6%, P=0.017), and the group switched from 
TZD (∆HbA1c=-0.3%, P=0.013). While HbA1c levels de-
creased significantly at visit 2, those from visit 2 through visit 
5 were not significantly different. The mean doses of the group 
switched from SU were 1.8 mg in the case of glimepiride 
Table 1. Baseline characteristics of subgroups classified by medication regimen
Characteristic (at visit 1) SITA+MET
 a 
(n=21)
Adding on MET 
(n=18)
Adding on SU 
(n=12)





Age, yr 53.4±9.7 49.8±10.7 55.8±10.4 58.8±13.5 49.8±10.7 54.1±11.5
53.0 (47.5, 61.0) 49.0 (44.8, 56.3) 56.0 (46.8, 64.8) 60.0 (55.0, 65.5) 52.5 (40.8, 59.5)
Duration of T2DM, yr 1.6±2.0 3.9±2.8 7.9±4.5 3.2±2.2 3.7±2.1 3.7±3.2
0.5 (0.1, 2.5) 3.3 (1.5, 5.0) 7.5 (3.5, 1.3) 2.9 (1.3, 4.4) 3.3 (2.3, 5.5)
Females, n (%) 13 (62) 15 (83) 9 (75) 10 (46) 9 (64) 56 (64.4)
BMI, kg/m
2  26.6±3.4 24.3±2.5 24.0±4.2 26.0±3.5 27.4±3.3 25.8±3.4
25.2 (24.2, 29.3) 24.4 (22.0, 26.9) 25.7 (19.8, 27.4) 25.2 (22.7, 28.1) 26.5 (24.6, 30.2)
HbA1c, %  7.3±1.1 7.1±0.8 7.7±0.6 6.8±0.6 7.3±1.1 7.2±0.9
7.0 (6.6, 7.8) 7.2 (6.4, 7.6) 7.6 (7.2, 8.2) 6.7 (6.3, 7.1) 7.0 (6.5, 7.7)
FPG, mg/dL 158.5±24.3 136.7±25.4 152.1±21.1 127.9±21.8 152.2±31.2 144.3±27.3
156 (138, 178) 137 (114, 152) 151 (130, 175) 122 (118, 148) 147 (131, 172)
Anti-hypertensive  
agent, n (%)
9 (42.9) 6 (33.3) 9 (75.0) 10 (45.5) 7 (50.0) 41 (47.0)
Anti-lipid agent, n (%) 7 (33) 11 (61.1) 9 (75.0) 13 (59.1) 11 (78.6) 55 (63.2)
MET agent, n (%) 21 (100) 18 (100) 11 (92) 20 (91) 13 (86) 82 (94.3)
Fasting insulin, μIU/mL 13.3±6.0 10.4±3.5 8.5±5.0 11.9±3.9 11.3±2.2 11.8±4.6
12.5 (7.8, 18.0) 9.1 (8.0, 11.7) 8.5 (4.9, 14.0) 11.9 (8.7, 14.6) 11.8 (9.6, 12.9)
Fasting C-peptide,  
ng/mL
4.0±1.6 2.4±2.5 2.1±1.0 3.2±0.8 3.1±0.8 3.3±1.3
3.4 (2.8, 5.5) 2.4 (2.1, 3.3) 2.1 (1.4, 3.1) 3.3 (2.8, 3.7) 2.9 (2.3, 3.9)
Data are presented as mean±standard deviation and median (25% confidence interval [CI], 75% CI) except female, using anti-hypertensive 
agent and anti-lipid agent and metformin agent (n [%]). 
SITA, sitagliptin; MET, metformin; SU, Sulfonylurea; TZD, thiazolidinedione; T2DM, type 2 diabetes mellitus; BMI, body mass index; FPG, 
fasting plasma glucose.
aDenotes initial combination of sitagliptin with metformin.293
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(n=18) and 30 mg in the case of gliclazide (modified- release 
form; MR) (n=4), but no statistically significant reductions 
were observed (∆HbA1c=-0.2%, P=0.63) (Table 2, Fig. 1). 
  The statistically significant reduction in FPG between visit 1 
and visit 5 (∆FPG) was only observed in the initial coadminis-
tration of SITA and MET group (∆FPG=-26.8 mg/dL, P=
0.002), and there were no significant changes in the group 
changed from SU (∆FPG=4 mg/dL, P=0.776), the add-on to 
SU group (∆FPG=-5.1 mg/dL, P=1.0), the add-on to MET 
group (∆FPG=2.36 mg/dL, P=0.74), or the group changed 
from TZD (∆FPG=-7.2 mg/dL, P=0.192) (Table 2, Fig. 2). 
  Side effects were reported in eight of the 99 patients. One 
patient showed symptoms of hypoglycemia, one patient had 
an increase in body weight, five patients showed signs of indi-
gestion, abdominal discomfort and gastrointestinal problems, 
and one patient reported problems with facial swelling. All pa-
tients who complained of gastrointestinal symptoms were be-
ing treated with MET combination therapy. There were no se-
rious adverse effects associated with SITA. 
Analysis on the treatment failure group
SITA treatment failure was experienced by 12 patients (five 
males, seven females): four patients changed from or added to 
insulin treatment, four patients added to MET treatment, one 
on the patient had initial combination of SITA with MET, one 
patient switching from SU, and one patient changed from TZD.
  Compared to 87 patients in the treatment maintenance group, 
the diabetes duration of the treatment failure group was longer 
(7.6 vs. 2.8 year, P=0.008), the HbA1c level at visit 1 was high-
er (8.6% vs. 7.0%, P=0.001) and the FPG was higher (193 vs. 
151 mg/dL, P=0.003). Age, gender, BMI, fasting insulin, and 
C-peptide level before taking the anti-diabetic drugs, history 
of hypertension, and hyperlipidemia were not significantly 
different between the treatment failure and maintenance group 
(Table 3).
Subanalysis on tertiles of ∆HbA1c in the treatment 
maintenance group
During treatment, the ∆HbA1c in the 87 patients who contin-
ued treatment were categorized into tertiles. Good response 
group (tertile 3 of ∆HbA1c) had a large improvement in blood 
glucose level, and low response group (tertile 1 of ∆HbA1c) 
experienced a small improvement in blood glucose level. Com-
pared to low response group, the HbA1c level at visit 1 of good 
response group was higher (7.5% vs. 6.6%, P<0.001) and the 
duration of diabetes was shorter (2.0 vs. 4.0 year, P=0.009); 
however, age, fasting glucose level, BMI, fasting insulin level, 
and C-peptide level were not significantly different between 
Table 2. Efficacy of subgroups on HbA1c and fasting plasma glucose change (∆HbA1c and ∆FPG) by sitagliptin from visit 1 to 
visit 5
HbA1c levels, % FPG, mg/dL
Baseline ∆HbA1c P value Baseline ∆FPG P value
SITA+MET
 a 7.3 -1.1±0.79 <0.001
 b 158.5 -26.8±14.1 0.002
 b
Adding on MET 7.1 -0.6±0.89 0.017
 b 136.7 2.4±22.9 0.74
Adding on SU 7.7 -0.5±0.58 <0.001
 b 152.1 -5.1±21.6 1.0
Swiching from SU 6.8 -0.2±0.67 0.63 127.9 4±28.9 0.776
Swiching from TZD 7.3 -0.3±0.71 0.013
 b 152.2 -7.2±25.2 0.192
FPG, fasting plasma glucose; SITA, sitagliptin; MET, metformin; SU, Sulfonylurea; TZD, thiazolidinedione.
aDenotes initial combination of sitagliptin with metformin, 
bStatistical significances were tested by Wilcoxon Signed Rank test.
Combination with MET


















  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5
Fig. 1. HbA1c change over time. MET, metformin; SU, Sulfo-
nylurea; TZD, thiazolidinedione. 
aDenotes significant reduc-
tion by according to the Wilcoxon Signed Rank test.294
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the two subgroups (Table 4). 
DISCUSSION
In this study, the treatment outcomes of SITA were analyzed at 
one university hospital for an average duration of ten months. 
The patients were divided into groups based on the classifica-
tion of treatment regimens and were retrospectively reviewed. 
Significant improvements in HbA1c and blood glucose levels 
were observed after a few months in the initial coadministra-
tion of SITA with MET group, the add-on to MET or SU groups 
and in the group switched from TZD. The efficacy of the SITA 
showed a similar effect as that of the SU, usually the minimum 
amount of commercial units.
  Although there were many complaints of gastrointestinal 
discomfort, all of them were from the group coadministrated 
with MET. Among those who complained, no clinically signif-
icant adverse effects were observed. Compared to the treat-
ment maintenance group, the duration of diabetes of the treat-
ment failure group was longer and the HbA1c and FPG were 
higher. However, the age, gender, BMI, fasting insulin, fasting 
C-peptide, antihypertensive medication, antihyperlipidemia 
medication history, and smoking history were not significant-
ly different in these groups.
  After the recent development of drugs that increase the lev-
els of the incretin hormones GLP-1 and GIP, it was found that 
commercialized DPP IV-inhibitor prolonged and enhanced 
incretin hormone activity. As a result of these drugs, insulin 
secretion from pancreatic β cells is stimulated based on blood 
sugar level; glucagon secretion from pancreatic α-cells is sup-
pressed to manage blood glucose, pancreatic cell dysfunction 
Table 3. Baseline demographic and clinical differences between the treatment failure group and the treatment maintenance 
group during observation period
Variable Treatment failure group Treatment maintenance group P value 
No. (%) 12 (12.1) 87 (87.9)
Age, yr 54.5 (42.5, 54.5) 55.0 (47.0, 62.0) 0.923
Female, n (%) 7 (58.3) 56 (64.4) 0.684
Duration of T2DM, yr 7.6 (2.5, 12.4) 2.8 (1.3, 5.0) 0.008
 a
HbA1c, % 8.6 (7.5, 10.1) 7.0 (6.6, 7.6) 0.001
 a
FPG, mg/dL 193 (152, 234)  145 (126, 157) 0.003
 a
BMI, kg/m
2 26.3 (20.3, 32.9) 25.4 (23.1, 27.6) 0.760
Fasting insulin, μIU/mL 9.3 (3.3, 14.1) 11.3 (8.4, 13.7) 0.367
Fasting C-peptide, ng/mL 2.4 (1.3, 4.0) 3.1 (2.4, 3.7) 0.382
Glycemic medication Hx., n (%) 10 (83.3) 66 (75.9) 0.566
Anti-hypertensive agent, n (%) 6 (50.0) 41 (47.1) 0.852
Anti-lipid agent, n (%) 5 (41.7) 51 (58.6) 0.267
Smoking, n (%) 3 (25.0) 19 (22.1) 0.821
Data are presented as median (25% confidence interval [CI], 75% CI) or number (%). 
T2DM, type 2 diabetes mellitus; BMI, body mass index.
aStatistical significances were tested by χ
2--test for categorical variables and Mann-Whitney test for continuous variables.
Combination with MET













  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5
Fig. 2. Fasting plasma glucose change over time. MET, metfor-
min; SU, Sulfonylurea; TZD, thiazolidinedione. 
aDenotes sig-
nificant reduction by according to the Wilcoxon Signed Rank 
test.295
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is prevented, and hypoglycemia and weight gain are rare 
[4,11,12].
  SITA (Januvia
®) is the first DPP IV-inhibitor that has been 
licensed for use in type 2 diabetes patients; It has been report-
ed to not affect the pharmacokinetics of other oral diabetes 
drugs such as MET, SU, and rosiglitazone [10,13]. The validity 
and reliability of SITA have been demonstrated in type 2 dia-
betes patients because blood glucose level is improved and 
side effects from SU or insulin-like treatment drugs such as 
hypoglycemia and weight gain are very uncommon. FDA ap-
proved the use of SITA in type 2 diabetes and drug indications 
are as follows: SITA monotherapy, combination therapy with 
MET, dual add-on therapy to SU, MET, TZD, triple oral thera-
py with MET, SU/TZD, and add-on to insulin. Domestically, 
however, only the add-on to MET has been acknowledged for 
uncontrolled type 2 diabetic patients.
  Several randomized double-blind clinical trials have evalu-
ated the efficacy of oral sitagliptin in type 2 diabetic patients 
with HbA1c level ranged from 6.5-8% to 10-12%. Initial coad-
ministration therapy of SITA with MET significantly lowered 
HbA1c, FPG and two-hour postprandial blood glucose levels 
more than did MET monotherapy after 24 weeks of treatment, 
and maintained the effect for 54 to 104 weeks [14-16]. When 
SITA was added to MET, the reductions in HbA1c and FPG 
were sustained during an 18- to 24-week observation period 
[17-19], and when added to SU, improvements in blood glu-
cose were maintained for 24 weeks [20]. Additionally, when 
100 mg of both SITA and MET were combined, there was no 
comparative difference in the level of reduction in HbA1c level 
between 52 weeks of MET and 5 mg glipizide [21] or 18 weeks 
of an 8-mg rosiglitazone and MET combination therapy [19]. 
In the present study, significant improvements in HbA1c level 
were found in every group except the group switched from SU. 
Two to three months after the initial treatment, the significant 
decrease in HbA1c level plateaued and was maintained for ten 
months. The group switched from SU was administered an av-
erage dosage of 1.8 mg glimepiride and an average dosage of 
30 mg gliclazide MR.
  Unlike HbA1c, FPG showed an immediate improvement 
only in the initial MET and SITA combination group. Howev-
er, the values of FPG in other four groups were less recorded 
and the standard deviation of FPG was higher than the stan-
dard deviation of the HbA1c. These results indicate a limita-
tion to our retrospective study. 
  The average body weight change in the patients in the group 
switched from TZD during the observation period was 1.1 kg, 
but it was not significant (n=14, P=0.124). The 18-week study 
by Scott et al. [19] demonstrated that, while the addition of 
TZD to MET gained an average of 1.5 kg, the addition of SITA 
to MET lost an average of 0.4 kg, a 1.9-kg difference between 
the two groups. Therefore, SITA can be used as an alternative 
to avoid the weight gain associated with TZD.
  In the meta-analysis of SITA, the risk of hypoglycemia is as-
sociated with the combination with SU or insulin treatment and 
gastrointestinal side effects is associated with MET [20,22,23]. 
In the present study, one patient who reported having hypo-
glycemia had previously taken SU, and the five patients who 
had reported gastrointestinal side effects were all taking MET; 
Table 4. Baseline demographic and clinical differences of treatment maintenance group according to HbA1c change (∆HbA1c, 
HbA1c at visit 1–HbA1c at visit 5) tertiles, excluding 2nd tertile group 
Variable 1st tertile (∆HbA1c ≤0.2%) 3rd tertile (∆HbA1c >0.7%) P value 
No. (%) 29 (33.3) 30 (34.5)
Female, n (%) 15 (52.0) 22 (73.0) 0.198
Age, yr 56.0 (48.0, 60.0) 55.0 (46.0, 65.0) 0.525
Duration of T2DM, yr 4.0 (2.5, 7.4) 2.0 (0.9, 3.0) 0.009
 a
HbA1c, % 6.6 (6.2, 6.9) 7.5 (7.1, 8.2) <0.001
 a
FPG, mg/dL 131 (118, 151) 151 (137, 170)  0.082
BMI, kg/m
2 26.7 (23.9, 29.1) 25.2 (23.8, 28.6) 0.861
Fasting insulin, μIU/mL 12.3 (8.7, 16.8) 10.4 (8.4, 13.4) 0.791
Fasting C-peptide, ng/mL 2.8 (2.3, 3.7) 3.4 (2.8, 3.9) 0.762
Data are presented as median (25% confidence interval [CI], 75% CI) or number (%). 
aStatistical significances were tested by Kruskal-Wallis and Bonferroni post-hoc analysis. 296
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the side effects of SITA monotherapy could not be determined.
  The duratin of diabetes (P=0.008), HbA1c (P=0.001) and 
FPG (P=0.003) in the treatment failure group were signifi-
cantly higher than those of the treatment maintenance group 
(Table 3). However, only a small number of patients were clas-
sified into the failure group, and more domestic participants 
are needed for further analysis.
  When ∆HbA1c of the treatment maintenance group were 
divided into three parts and analyzed, the low response group 
had a longer diabetes duration (P=0.009) as well as a lower 
initial HbA1c level (P<0.001) (Table 4). However, the low re-
sponse group did not mean treatment failure and our results 
suggest that the efficacy of sitaglitin therapy is noninferior to 
that of other common diabetes drugs such as SU. Additionally, 
the grehlin hormone and the parasympathetic nervous system 
are involved in the regulation of GLP-1 [24,25] and genetic 
polymorphisms of GLP-1 receptors have been reported [26]. 
Further understanding the individual responses to fats and 
carbohydrates and GLP-1 receptor will help predict non- or 
less-responders to SITA.
  This study had several limitations. First, we only selected 
subjects at a single university hospital and the number of avail-
able participants in each group was small due to the selection 
criteria and classification. Second, the retrospective approach 
lost some data of clinical and biochemical parameters. Third, 
the preservation of pancreatic β-cell function from SITA ad-
ministration could not be confirmed clinically since oral glu-
cose tolerance tests were not usually performed after adminis-
tration of SITA. However, according to most of the other re-
ports, significant improvements in the homeostasis model of 
assessment of β-cell function (HOMA-β), the proinsulin-to-
insulin ratio, and the insulinogenic index were reported [10, 
14,17,18,23]. SITA was found to have no effect on insulin re-
sistance or sensitivity as reflected by HOMA-IR and the quan-
titative insulin sensitivity check index (QUICKI) [18,20,27]; 
on the other hand, some reports showed significant improve-
ments in insulin resistance or sensitivity [17,28].
  In summary, SITA is efficient for glycemic controls in the 
cases of the initial coadministration with MET, the add-on 
therapy to MET or SU and administration switched from TZD 
or SU. It is also relatively safe over an average of ten months in 
Korean type 2 diabetes. However, well-designed, prospective 
and long-term studies are needed to understand the treatment 
failure or response of SITA. 
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